Zura Bio (NASDAQ:ZURA) Stock Gets Price Target Trim from Oppenheimer

Zura Bio (NASDAQ:ZURA – Free Report) had its price objective decreased by Oppenheimer to $5.00 in a research report report published on Tuesday morning,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

ZURA has been the topic of a number of other research reports. Wedbush boosted their price objective on Zura Bio from $15.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. Guggenheim reissued a “buy” rating on shares of Zura Bio in a research report on Friday, October 30th. Weiss Ratings upgraded Zura Bio from a “sell (d-)” rating to a “sell (d)” rating in a report on Wednesday, October 28th. Finally, Wall Street Zen raised Zura Bio from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $14.50.

Check Out Our Latest Stock Analysis on Zura Bio

Zura Bio Stock Performance

ZURA stock opened at $1.24 on Tuesday. The firm has a market capitalization of $119.44 million, a price-to-earnings ratio of -1.11 and a beta of 0.03. The company’s 50 day moving average price is $4.11 and its 200 day moving average price is $5.11. Zura Bio has a fifty-two week low of $0.93 and a fifty-two week high of $7.44.

Zura Bio (NASDAQ:ZURA – Get Free Report) last released its quarterly earnings results on Tuesday, October 27th. The company reported ($0.20) EPS for the quarter, hitting the consensus estimate of ($0.20). Equities analysts forecast that Zura Bio will post -0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Ethic Inc. purchased a new position in Zura Bio in the third quarter valued at approximately $53,000. Dimensional Fund Advisors LP grew its holdings in shares of Zura Bio by 83.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 43,135 shares of the company’s stock valued at $257,000 after purchasing an additional 19,603 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Zura Bio by 2,534.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 124,174 shares of the company’s stock valued at $517,000 after acquiring an additional 119,460 shares during the last quarter. Alps Advisors Inc. raised its holdings in Zura Bio by 30.7% during the 3rd quarter. Alps Advisors Inc. now owns 126,053 shares of the company’s stock valued at $524,000 after buying an additional 29,639 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Zura Bio by 3,007.7% during the first quarter. Bank of America Corp DE now owns 136,523 shares of the company’s stock valued at $812,000 after acquiring an additional 132,130 shares in the last quarter. 61.14% of the stock is owned by institutional investors.

Zura Bio Company Profile

(Get Free Report)

Zura Bio is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. Its research targets immune pathways that may contribute to a range of chronic conditions. The company’s investigational pipeline includes tibulizumab (ZB-106), a dual-targeting antibody designed to inhibit BAFF and IL-17A, and ZB-168, an antibody targeting the IL-7 receptor alpha. These candidates are being developed for potential use in autoimmune and inflammatory conditions.

Recommended Stories

Analyst Recommendations for Zura Bio (NASDAQ:ZURA)

Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.